Upgrade to SI Premium - Free Trial

Leerink Partners Downgrades Regeneron Pharma (REGN) to Market Perform, 'on LAG-3 Failure and Eylea Erosion Risk'

May 18, 2026 6:05 AM
(Updated - May 18, 2026 1:08 PM EDT)

Leerink Partners analyst Andrew Berens downgraded Regeneron Pharma (NASDAQ: REGN) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments Analyst PT Change Downgrades

Next Articles